Cardinal Health Inc. Stock

Cardinal Health (CAH.US) – FY2025 Annual Report

Cardinal Health’s financial position at the close of FY2025 appears to reflect a period of significant operational improvement, even as the top line contracted slightly. The revenue decline of just under 2% to approximately $222.6 billion seems to mask a more fundamental strengthening of the underlying business, as net income nearly doubled from the prior year. This divergence between revenue and profit trends could suggest that recent strategic initiatives—particularly around specialization and cost efficiency—are beginning to deliver tangible results, though the company continues to operate with a negative equity position that warrants ongoing attention.

The most notable development in the income statement may be the expansion of profitability metrics across the board. Gross margin improved from 3.27% to 3.67%, while operating margin nearly doubled from 0.55% to 1.02%, culminating in a net margin of 0.70% compared to just 0.38% in FY2024. The two-year trajectory appears even more striking, with net income growing more than fourfold since FY2023. This improvement seems to be driven by a combination of factors: gross profit grew by roughly 10% on lower revenue, while impairment charges and litigation costs declined sharply. The GMPD segment, which had been a drag on profitability in prior years, appears to have moved into more stable territory, while the “Other” segment—comprising the higher-growth units—continued to expand its contribution. The Pharma segment remains the dominant profit engine, delivering over $2.2 billion in operating earnings.